Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i expact news earliest on mid January and latest on end February.
playyyer
Volume yesterday 200
Peter Chin is happy too.
I send him my congratulations yesterday and he answered very happy.
playyyer
You are welcome
my day is made too
PETER CHIN IS GREAT
show me an other stock who got this
WE ARE BACK
ON NOVEMBER 30, 2010 THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION DECLARED DISABILITY ACCESS CORPORATION'S FORM 10 REGISTRATION STATEMENT EFFECTIVE AND APPROVED, CLEARING THE PATH FOR DISABILITY ACCESS CORPORATION'S POSSIBLE LISTING ON THE OTC BULLETIN BOARD.
insert-text-here
ok, sorry.
Maybe tomrrow or Monday.
We will see.
I hope so!!!!!
i think the 10K and Q´s are the last requests from the SEC.
So the deadline 30 days counts from 25.10.2010.
The SEC answer must be near, maybe today or tomorrow.
playyyer
Following several queries from the investment community, PTSH explains the
relationship with ThinLine and addresses its "70% ownership". Raj Kalra, CEO of
PTSH explains, "PTSH purchased my 70% ownership of ThinLine in a Share Exchange
Agreement last week. In exchange of my 70% ownership I received restricted
shares of PTSH stock. ThinLine has two owners, PTSH (70%) and a second party
(30%). ThinLine is a subsidiary of PTSH, owning 70% therefore shall receive 70%
of the profits. In respect to why the deal won't close until December 31, 2010
is due to two factors: 1) ThinLine has approx 70 days to complete SEC audits
and; 2) PTSH has its year end 12/31/10, and it makes for easier accounting. For
all intensive purposes it is business as usual for PTSH and ThinLine since the
merger.
insert-text-here
For me it is a good sign, that Peter is still trying his best to bring us back to market....
We will see...
I think this year it can be done.
10Q is out!!!
Post Unavailable
Additional Information
Post Unavailable
Additional Information
PTSH Merger News and 8k out
tomorrow gapper
PTSH Merger News and 8k out
run for tomorrow
PTSH News and 8k out
for shure "registered" not "restricted"
see 10-Q/A from today
Explanatory Note:
In response to comments received from the Staff of the Securities and Exchange Commission (“SEC”) Disability Access Corporation is filing this Amendment No. 3 to our Quarterly Report on Form 10-Q/A Amendment No. 2 filed on October 22, 2010 to amend and restate the Registrant’s certification filed as Exhibit 32.
playyyer
Round 10 is answered
PTSH 0.0015
0,0013
PTSH looks good will play it
hi mmech,
what do you mean with "mini-mergers"??
How much volume of sales mean "mini"
thx
playyyer
NEWS
Diamant Art Announces T&R's Entrance Into the Chinese Market Through One of the Country's Top Fortune 500 Companies
Aug 25, 2010 7:00:00 AM
Close Ad
Email story | Discuss on ZenoBank | View more ads
TORONTO -- (MARKET WIRE) -- 08/25/10 -- Diamant Art Corporation (PINKSHEETS: DIAAF) (FRANKFURT: HGHN), a publicly traded INTERNATIONAL company that assists businesses in boosting revenues and decreasing expenses through its product management and security solutions, has announced that its wholly owned subsidiary -- T&R International (http://www.thinkandreact.com), is entering into a significant partnership that will begin to generate a demand for T&R's range of products in China beginning in September of this year.
T&R's Partner, a notable Fortune 500 company in China, has been educated in the structure and functionality of the Company's Green Tec hardware and software, Shift Planning software, stolen goods recognition equipment. The Company is completing preparations to provide 24-hour territory wide customer support.
This Company's primary prospects in China include current Municipalities, Building Management Companies, Government and Factories.
This enterprise represents the Company's entrance into the biggest growing market in the world.
T&R is going to start with installation of the Green Tec technology and the RFID management control hardware and software and security control in one of the largest factories in China for NANO Technology.
In the USA market T &R is already poised and is underway to its 180th Hospital installations.
With approximately 7,500 Hospitals in the USA and forecasting another 1,500 installations over the next 3 years with the Green Tec hardware and software revenues at an average of $130,000 for each of the Green Tec Hardware installation, the gross revenues could exceed $195,000,000 on the Green Tec Hardware revenues alone. The Green Tec software revenues could also exceed another $300,000,000 within three years in the Hospital market.
These figures do not even address potential income from the Mall, Factories, Shops, Office buildings, train stations, Hotels and Convention centers.
hope so
NT-10Q 10Q expected 24.05.2010
don´t miss zhe PTSH train
there is no trading in Frankfurt,
only Stuttgart have volumen
PTSH 0,0027-0,0028
have a look at PTSH
10K comes out today
CNOA NEWS 23.03.2010
China Organic Agriculture, Inc. Completes Acquisition of Changbai Eco-Beverage, a Blueberry Product Producer
LIAONING, China, Mar 23, 2010 (BUSINESS WIRE) -- China Organic Agriculture, Inc. (OTCBB: CNOA) ("China Organic Agriculture" or the "Company"), a company headquartered in the Liaoning Province in China engaged in the trading and distribution of agricultural products, today announced that it has completed acquiring 60% of the stock of Changbai Eco-Beverage Co., Ltd. ("Changbai") for RMB70 million ($10.25 million).
Located in the Liaoning Province in China, Changbai is mainly engaged in the research, production and sale of various natural products including blueberry drinks, blueberry health care products, and bee products to meet the increasingly market demands in China for these goods. The Chinese economy's dramatic rise in the disposable income has increased the demand for "green foods" such as those provided by Changbai.
Founded in May 2008, Changbai estimates that it achieved a net income of approximately RMB15 million in 2009. With the strong demand for its products, Changbai plans to expand its blueberry distribution on a national basis, thus increasing its market share in the Chinese blueberry segment, and its recognition as a quality producer of organically friendly products.
As a result of becoming a part of the China Organic Agriculture's family, Changbai will be able to more quickly expand both its distribution and its product mix in China's expanding blueberry market. By utilizing the Company's existing distribution network, Changbai will be able to do this while benefiting its distribution efficiencies and overall profitability.
About China Organic Agriculture
China Organic Agriculture is based in China and is primarily engaged in the acquisition, trading and distribution of agricultural products. For more information, please visit: http://www.chinaorganicagriculture.com.
FORWARD-LOOKING STATEMENTS: Except for historical information, this press release contains forward-looking statements which reflect the China Organic Agriculture's current expectations regarding future events. These forward- looking statements involve risks and uncertainties, which may cause actual results to differ materially from those statements. Those risks and uncertainties include, but are not limited to, changing market conditions and other risks detailed from time to time in China Organic Agriculture's ongoing quarterly filings and annual reports. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events in this press release might not occur.
Forward-looking statements include, but are not limited to, statements concerning future acquisitions, including the acquisition of Changbai, estimates of, and increases in, production, cash flows and values, statements relating to the continued advancement of China Organic Agriculture's products and other statements which are not historical facts. When used in this document, words such as "could," "plan," "estimate," "expect," "intend," "may," and similar expressions denote forward-looking statements. Although China Organic Agriculture Inc. believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Important factors that could cause actual results to differ from these forward-looking statements include, but are not limited to, those set forth in our reports filed with the Securities and Exchange Commission, together with the risks discussed in our press releases and other communications to shareholders issued by us from time to time, such as our ability to raise capital as and when required, the availability of raw products and other supplies, competition, the costs of goods, government regulations, and political and economic factors in the People's Republic of China in which our subsidiaries operate.
SOURCE: China Organic Agriculture, Inc.
CONTACT:
China Organic Agriculture, Inc. Hans Shen, +1-707-709-2321 IR@cnoainc.com
Copyright Business Wire 2010
-0-
KEYWORD: United States
China
Asia Pacific
North America
California
INDUSTRY KEYWORD: Natural Resources
Agriculture
SUBJECT CODE: Merger/Acquisition
LEGEND INTERNATIONAL HOLDINGS INC. PHOSPHATE PROJECT - FURTHER MILESTONES AND PROJECT UPDATE
Melbourne Australia – March 16, 2010 – Legend International Holdings, Inc (OTCBB: LGDI) is pleased to announce a number of milestones for its Queensland Phosphate Project including recent initial findings from the feasibility study being conducted by Wengfu, metallurgical results, and the initial JORC resource estimate for the central core of its 100% owned Paradise North Phosphate Deposit (EPM 17330). For the full results and technical report (Form 8-K) please visit Legend’s website www.lgdi.net. The highlights of this report are:
• Wengfu (Group) Co. Ltd’s delegation of 7 technical experts completes visit to Legend’s Phosphate deposits and associated facilities in Australia to further the current feasibility test work that is currently being undertaken by Wengfu. Initial findings and recommendations are very positive.
• Upon completion of a positive feasibility study, Wengfu will become an equity partner with Legend and assist with obtaining further financing options for the project.
• Recent metallurgical testwork conducted in the U.S.A has proven that material from Paradise North acidulates well and makes a world market quality phosphoric acid.
• Queensland’s Department of Infrastructure and Planning have reserved over 740 acres of suitable land for the development of a phosphoric acid plant located 5km south of Mt Isa for Legend’s Phosphate Project.
• 2009 Pilot Beneficiation Plant testwork concludes, proving the internally designed flowsheet for flotation of phosphate rock concentrate successfully upgrades rock up to 35% P2O5.
• Initial DSO targeted JORC resource estimate of 7.3 Mt @ 28.1% P2O5 for the currently drill tested central core (less than 5% of historical resource area) of the Paradise North deposit (EPM 17330).
• Legend’s project schedule will be based on Wengfu’s feasibility study recommendations.
• IFFCO remains a strong strategic partner willing to off take rock and fertiliser products.
• Indian government to send delegation, including the Minister of Fertilizers and the Managing Director of IFFCO, to visit Legend’s Phosphate Project and Queensland State Ministers on March 23, 2010.
• Legend intends to spin out to a new company the diamond, gold and base metal interests of Legend of which Legend shareholders will receive shares of common stock on a pro rata basis to the shares they hold in Legend. Following the spin out, Legend will be a 100% pure phosphate company.
Forward-Looking Statements
Forward-looking statements in this press release are made pursuant to the “safe harbour” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, the risks of exploration and development stage projects, risks associated with environmental and other regulatory matters, mining risks and competition and the volatility of mineral prices. Actual results and timetables could vary significantly. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s fiscal 2008 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.
For further information, please contact:
Mr. Joseph Gutnick
General Manager Business
Chief Executive Officer
New York Office
Legend International Holdings, Inc.
Legend International Holdings, Inc.
Tel: +011 613 8532 2866
Tel: (212) 223 0018
Fax: +011 613 8532 2805
Fax: (212) 223 1169
E-mail: josephg@axisc.com.au
E-mail: legendinfo@axisc.com.au
new 8-K is out
absolute correct PTSH now is a POS
Generex receives positive responses from independent physicians and nurse practitioners in recent fo
March 11, 2010
Generex receives positive responses from independent physicians and nurse practitioners in recent focus groups conducted in the United States for Generex Oral-lyn™
WORCESTER, MA, March 11, 2010 (GlobeNewswire) – Generex Biotechnology Corporation (NasdaqCM:GNBT, www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Health Management Resources, Inc. (HMR) has recently conducted two focus groups in Indianapolis for Generex Oral-lyn™. HMR provides educational programs, materials, and services to the healthcare industry. Specializing in diabetes management, HMR has collaborated with medical associations and industry to develop clinical practice guidelines and to facilitate delivery of diabetes-related information and education to healthcare providers and people with diabetes.
The focus groups were conducted with one group consisting of physicians and another consisting of nurse practitioners. The focus groups were designed to determine the perception and opinions of these healthcare practitioners regarding the Generex’s buccal insulin spray, Generex Oral-lyn™. The opinions expressed by both groups were very positive regarding the product and the general consensus was that Generex Oral-lyn™ is a suitable alternative prandial insulin product. Participants also expressed interest in the expanded access Treatment IND program in respect of the product, additional information in respect of which can be obtained on the www.ClinicalTrials.gov website.
Generex announced in September 2009 that the USFDA has granted approval for the treatment use of Generex Oral-lyn™ in patients with Type 1 or Type 2 diabetes mellitus under the FDA’s expanded access Treatment IND program. Under the expanded access Treatment IND protocol, Generex Oral-lyn™ will be provided to patients with life-threatening or serious Type 1 or Type 2 diabetes mellitus where there is no satisfactory alternative therapy available to treat the condition.
Generex Oral-lyn™ is the Company’s proprietary buccal insulin spray product for the treatment of patients with Type 1 or Type 2 diabetes mellitus, impaired glucose tolerance (IGT) or pre-diabetes. The product is presently in a global Phase III protocol clinical trial in patients with Type 1 diabetes mellitus.
“We are pleased with the results of these initial focus groups as we prepare for our initial distribution under the Treatment IND program,” said Anna Gluskin, the Company’s President & Chief Executive Officer. “We believe that Generex Oral-lyn™ will play an important role in redefining the diabetes treatment paradigm and that these educational forums will provide valuable information to help us gain the confidence of physicians and nurse practitioners who treat diabetes patients on a daily basis.”
The FDA’s expanded access Treatment IND Program allows companies to provide early access to investigational drugs for patients with serious or life-threatening conditions for which there is no satisfactory alternative treatment. Generex Oral-lyn™ qualified for the Program after its safety and efficiacy was demonstrated over 10 years of development and clinical studies.
To learn more about the availability of Generex Oral-lyn™ under the Program, as per FDA requirements, the Company has provided information pertaining to the Program within the www.ClinicalTrials.gov website. Details include treatment design and participating sites and/or physicians. Please note that the drug will be available only through qualified investigators who are registered in the Program.
About Generex Biotechnology Corporation
Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which has been launched in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Safe Harbor Statement
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any “phase” of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contacts:
Investor Relations Contact:
American Capital Ventures, Inc.
Howard Gostfrand
1-877-918-0774
Media Contact:
Beckerman Public Relations
Angelene Taccini
201-488-0049
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7118961" rel="nofollow" target="_blank" >http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7118961
http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7118908" rel="nofollow" target="_blank" >http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=7118908
@fallback thx for updating the iBox
Alert PTSH with new CEO
http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=28860307&topic=PTSH&symbology=null&cp=off&webmasterId=89753" rel="nofollow" target="_blank" >http://app.quotemedia.com/quotetools/newsStoryPopup.go?storyId=28860307&topic=PTSH&symbology=null&cp=off&webmasterId=89753